Conjugate Vaccine Market, By Product Type, By Disease Indication, By Pathogen Type, By Patients Type, By Geography

Description

Conjugate Vaccine Market is estimated to be valued at USD 25,966 Mn in 2026 and is expected to reach USD 49,220 Mn by 2033, growing at a compound annual growth rate (CAGR) of 9.6% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 25,966 Mn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	9.60%	2033 Value Projection:	USD 49,220 Mn

Conjugate vaccine is a combination of a weak antigen with a strong antigen so as to provide active immunization against immune system having a stronger response to the weak antigen. In a conjugate vaccine, the weak antigen is covalently attached to a strong antigen and triggers stronger immunological response to the weak antigen. The weak antigen is a polysaccharide that is attached to strong protein antigen.

Conjugate vaccines target several leading causes of vaccine-preventable deaths. Advantages of conjugate vaccines include their ability to elicit immunological memory and to reduce asymptomatic carriage of the bacteria, resulting in marked herd immunity. These vaccines offer immunization from different bacterial strains. For instance, on January 24, 2022 according to the Centers for Disease Control and Prevention (CDC) April 2019 data, pneumococcal conjugate vaccine (called PCV13) protects against 13 types of pneumococcal bacteria. Whereas in 2021, US FDA (Food and Drug Administration) licensed PCV15 and PCV20 for use in adults 18 years or older. Clinical trial data showed that PCV15 and PCV20 caused the body's immune system to create antibodies, which helped fight the pneumococcal bacteria, similar to PCV13.

Market Dynamics

Increasing prevalence of pneumonia cases are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in August 2021, National Center for Biotechnology Information, published a report on Community-Acquired Pneumonia, which reported that the estimated worldwide incidence of community-acquired pneumonia varies between 1.5 to 14 cases per 1000 person-years, and this is affected by geography, season, and population characteristics. In the U.S., the annual incidence is 24.8 cases per 10,000 adults with higher rates as age increases, whereas the mortality rate is as high as 23% for patients admitted to the intensive care unit.

Increasing initiatives taken by the governments of countries to launch new vaccines are expected to drive growth of the global conjugate vaccine market over the forecast period. For instance, in October 2021, Union Health Minister (India), Dr. Mansukh Mandaviya, launched a nationwide expansion of Pneumococcal 13-valent Conjugate Vaccine (PCV) under the Universal Immunization Programme (UIP) as a part of Azadi ka Amrit Mahotsav. Whereas, on the other hand communication and awareness packages on PVC were also made available in India.

Key features of the study

This report provides an in-depth analysis of the global conjugate vaccine market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2022 - 2030), considering 2021, as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by key players
It profiles key players in the global conjugate vaccine market based on following parameters - company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include, Sanofi S.A, Pfizer, Inc., Merck & Co., Inc., GlaxoSmithKline plc., Bharat Biotech, Serum institute of India Pvt. Ltd., Biological E. Limited, Bio-Med, Bavarian Nordic, CSL Limited, Novartis AG, Vaxcyte, GSBPL, Taj Pharmaceuticals Limited, and Bavarian Nordic
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
The global conjugate vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through the various strategy matrices used in analyzing the global conjugate vaccine market

Market Segmentation

Product Type Insights (Revenue, USD Mn, 2026 - 2033)
- Monovalent Conjugate Vaccine
- Multivalent Conjugate Vaccine
Disease Indication Insights (Revenue, USD Mn, 2026 - 2033)
- Pneumococcal
- Influenza
- Meningococcal
- Typhoid
Pathogen Type Insights (Revenue, USD Mn, 2026 - 2033)
- Bacterial
- Viral
Patients Type Insights (Revenue, USD Mn, 2026 - 2033)
- Pediatric
- Adults
Regional Insights (Revenue, USD Mn, 2026 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
Key Players Insights
- Sanofi S.A
- Pfizer, Inc.
- Merck & Co., Inc.
- GlaxoSmithKline plc.
- Bharat Biotech
- Serum institute of India Pvt. Ltd.
- Biological E. Limited
- Bio-Med
- Bavarian Nordic
- CSL Limited
- Novartis AG
- Vaxcyte
- GSBPL
- Taj Pharmaceuticals Limited
- Bavarian Nordic

Product Code: CMI2697

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
Market Definition and Scope
Executive Summary
- Market Snapshot, By Product Type
- Market Snapshot, By Disease Indication
- Market Snapshot, By Pathogen Type
- Market Snapshot, By Patient Types
- Market Snapshot, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
- Restraints
- Market Opportunities
Impact Analysis
Market Trends
Key Developments
Product Pipeline Analysis
Investments and Government Initiatives
GAVI and PATH Program Details
Merger and Acquisition
Regulatory Scenario
PORTER'S Five Forces
PEST Analysis

4. Global Conjugate Vaccine Market, By Product Type, 2026-2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Monovalent Conjugate Vaccine
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Multivalent Conjugate Vaccine
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

5. Global Conjugate Vaccine Market, By Disease Indication, 2026-2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Pneumococcal
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Influenza
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Meningococcal
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Typhoid
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

6. Global Conjugate Vaccine Market, By Pathogen Type, 2026-2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Bacterial
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Viral
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

7. Global Conjugate Vaccine Market, By Patient Type,2026-2033, (USD Mn)

Overview
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Paediatric
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends
Adult
- Market Share Analysis, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, 2021 - 2033
- Segment Trends

8. Global Conjugate Vaccine Market, By Region, 2026-2033, (USD Mn)

Introduction
- Market Share Analysis, By Region, 2025, 2028, and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2021 - 2033
North America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
- Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.S.
  - Canada
Latin America
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
- Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Europe
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
- Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - U.K.
  - Germany
  - Italy
  - France
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
- Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - China
  - India
  - Japan
  - ASEAN
  - Australia
  - South Korea
  - Rest of Asia Pacific
Middle East
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
- Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Market Share Analysis, By Country, 2025, 2028 and 2033 (%)
- Y-o-Y Growth Analysis, For Country, 2021 - 2033
- Market Size and Forecast, By Product Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Disease Indication, 2026-2033, (USD Mn)
- Market Size and Forecast, By Pathogen Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Patient Type, 2026-2033, (USD Mn)
- Market Size and Forecast, By Country, 2026-2033, (USD Mn)
  - North Africa
  - Central Africa
  - South Africa

9. Competitive Landscape

Heat Map Analysis
Company Profile
- Sanofi S.A
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Pfizer, Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Merck & Co., Inc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- GlaxoSmithKline plc.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Bharat Biotech
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Serum institute of India Pvt. Ltd
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Biological E. Limited.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Bio-Med
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Biological E Limited
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- CSL Limited
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Novartis AG
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Vaxcyte
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- GSBPL
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Taj Pharmaceuticals Limited.
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
- Bavarian Nordic
Company Highlights
Product Portfolio
Financial Performance
Recent Highlights
Market Strategies
Analyst Views

10. Section

References
Research Methodology
About Us